James Carthew, head of investment companies at Quoteddata asked whether the share buyback suggestion was “too little, too late” for Shin Nippon. After a year of abysmal performance ...

Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update. Shin Nippon Biomedical Laboratories reported a 5.3% increase in revenue for the six months ending September 2024 ...

Jan 18 (Reuters) - The U.S. health regulator has declined to approve Japan-based Shin Nippon Biomedical Laboratories' treatment for acute migraine late on Wednesday, citing manufacturing concerns.

(RTTNews) - Satsuma Pharmaceuticals Inc. (STSA) agreed to be acquired by Shin Nippon Biomedical Laboratories Ltd. for $0.91 in cash per share at the closing of the transaction plus one non ...